Profound Medical Corp.
TSX:PRN.TOMedical - Devices
+$0.11 today
- Market cap
- $360.04M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.00M
Average 0.01M
PRN.TO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Profound Medical Corp.TSX: PRN.TO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $1.05M rose 6.0% year over year, behind the +98.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 24.1% from the prior quarter. Over 3 fiscal years it compounded at +9.0% a year.
Context
- Stock-based compensation amounted to 33.5% of revenue in FY2025, up 9.4 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +6.0% toward the trailing-twelve-month pace of +98.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 5.49M USD
- Year-over-year change
- +112.7%
- 4-year CAGR
- -6.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.49M | +112.7% |
| FY2024 | 2024-12-31 | 2.58M | -24.5% |
| FY2023 | 2023-12-31 | 3.42M | -19.4% |
| FY2022 | 2022-12-31 | 4.24M | -41.2% |
| FY2021 | 2021-12-31 | 7.21M | — |
Stock-Based Compensation vs competitors
How PRN.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +98.0% is the 3rd highest of 6, against a peer median of +5.0%.
- Stock-based compensation amounts to 29.6% of revenue for PRN.TO, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.67M USD | +143.3% | +84.7% | — | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $5.55M USD | +98.0% | +9.0% | 29.6% |
| LTM Mar 2026 | CA$4.81M CAD | +5.0% | +9.4% | 3.0% | |
| LTM Mar 2026 | CA$2.25M CAD | -37.4% | -15.9% | 0.6% | |
| LTM Mar 2026 | $1.4M USD | -30.3% | -13.2% | 2.5% | |
| LTM Mar 2026 | $246K USD | +228.0% | — | 0.1% | |
| Peer median (excluding PRN.TO) | — | +5.0% | -1.9% | 1.6% | |
Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.7M) | (28.67M) | (28.32M) | (27.82M) | (42.57M) |
| Depreciation & Amortization | 1.88M | 1.6M | 1.15M | 936K | 569.8K |
| Deferred Income Tax | (293K) | 0 | 232K | 0 | 0 |
| Stock-Based Compensation | 7.21M | 4.24M | 3.42M | 2.58M | 5.49M |
| Change in Working Capital | (877K) | (5.63M) | 540K | 591K | (1.74M) |
| Accounts Receivables | 2M | (1.93M) | (1.41M) | 186K | (175.01K) |
| Inventory | (2.49M) | (1.86M) | 353K | 656K | (2.87M) |
| Accounts Payables | (356K) | (566K) | 1.36M | 815K | 384.62K |
| Other Working Capital | (26K) | (1.27M) | 244K | (1.07M) | 918.81K |
| Other Non-Cash Items | 425K | 2.66M | 379K | 255K | (622.65K) |
| Operating Cash Flow | (22.36M) | (25.8M) | (22.61M) | (23.45M) | (38.88M) |
| Capital Expenditures | (593K) | 0 | 0 | 0 | (179.08K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (583.04K) | 0 | 0 | 0 | (246.24K) |
| Debt Repayment | (386K) | 6.92M | (1.2M) | (2.56M) | (1.33M) |
| Common Stock Issued | 6.32M | 255.17K | 2.71M | 62.11M | 43.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.03K | (141.17K) | 248.74K | (4.85M) | 0 |
| Financing Cash Flow | 5.95M | 7.03M | 1.76M | 54.7M | 41.86M |
| Effect of Forex Changes | 244K | (1.87M) | 549K | (2.54M) | (630.95K) |
| Net Change in Cash | (16.76M) | (20.64M) | (20.3M) | 28.7M | 2.11M |
| Free Cash Flow | (22.95M) | (25.8M) | (22.3M) | (23.45M) | (39.05M) |
Profound Medical Corp.
TSX:PRN.TO
Intrinsic Alpha fair value
Locked
Current Price
$9.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.